Medical Device Classification Compared: FDA vs EU MDR vs UK vs IMDRF

A comparative guide to medical device risk classification across the US (FDA), EU (MDR), UK (MHRA), and IMDRF frameworks, featuring worked examples of classification divergence.

For medical device manufacturers targeting global markets, risk classification is the foundation of your regulatory strategy. Before you can write a test protocol, compile a technical file, or calculate a registration budget, you must know your device's risk class in each target jurisdiction.

Risk classification dictates:

The regulatory pathway (e.g., whether you can self-certify or must undergo a third-party audit).
The clinical evidence requirements (e.g., whether bench data is sufficient or prospective clinical trials are mandatory).
The costs and timelines (e.g., Notified Body fees, FDA premarket user fees, and review times).

However, there is no single, globally unified classification system. While the International Medical Device Regulators Forum (IMDRF) has established harmonized principles, major jurisdictions maintain distinct approaches. The United States FDA uses a database-driven product code system. The European Union MDR uses a rules-based system. The United Kingdom is transitioning its framework post-Brexit. Meanwhile, dozens of other countries align directly with the IMDRF’s four-class model.

As a result, the exact same device can land in different classes in different markets, requiring entirely different compliance programs.

This article delivers a detailed comparison of the four major medical device classification frameworks: the US Food and Drug Administration (FDA), the European Union Medical Devices Regulation (EU MDR), the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and the International Medical Device Regulators Forum (IMDRF). We examine how each system works, compare their structures side-by-side, analyze software-specific rules, and walk through worked examples of classification divergence.

For single-system details, see our guides on FDA device classification, EU MDR classification rules under Annex VIII, and EU IVDR classification rules.

1. Overview of the Four Classification Systems

To compare these frameworks, we must first understand the logic that drives each system.

United States (FDA): Product-Code-Based Classification

The FDA classification system is established under Section 513 of the FD&C Act. It divides medical devices into three risk classes:

Class I (Low Risk): Subject only to General Controls (e.g., registration, listing, labeling, and CGMP/QMSR recordkeeping). Most are exempt from premarket notification.
Class II (Moderate Risk): Subject to General Controls and Special Controls (e.g., performance standards, postmarket surveillance, and patient registries). Most require a 510(k) submission.
Class III (High Risk): Subject to General and Special Controls, plus premarket approval (PMA) proving safety and effectiveness.

Rather than applying abstract rules to classify a device, the FDA uses a database of approximately 7,000 active product codes (Procodes). Each three-letter code is linked to a specific regulation in 21 CFR Parts 862–892, which defines the device class.

To see the distribution of these codes, we analyzed the complete FDA product classification database. Out of 7,075 active product codes:

Class II: 3,624 product codes (51.22%)
Class I: 2,401 product codes (33.94%)
Class III: 530 product codes (7.49%)
Unclassified / Not Classified / Other: 520 product codes (7.35%)

This distribution shows that over half of all FDA-recognized device types are Class II, requiring a 510(k) premarket notification unless specifically exempted.

European Union (EU MDR): Rules-Based Classification

The EU MDR (Regulation (EU) 2017/745) uses a rules-based system detailed in Annex VIII. It classifies devices into four risk categories:

Class I (Low Risk): Subdivided into Class I (standard, self-certified), Class Is (sterile), Class Im (measuring function), and Class Ir (reusable surgical instruments).
Class IIa (Medium-Low Risk): Requires Notified Body involvement for conformity assessment of the technical file.
Class IIb (Medium-High Risk): Requires Notified Body review, often involving specific product type examinations.
Class III (High Risk): Subject to maximum Notified Body scrutiny, clinical evaluation reviews, and active postmarket clinical follow-up (PMCF).

Annex VIII contains 22 rules grouped into four categories: Non-invasive devices (Rules 1–4), Invasive devices (Rules 5–8), active devices (Rules 9–13), and Special rules (Rules 14–22). Under the EU framework, the manufacturer must apply all 22 rules to their device. Where multiple rules apply, the rule resulting in the highest classification governs.

Historically, Class I devices have dominated the European market, representing approximately 70% of all medical devices in circulation (largely consisting of basic consumables, reusable instruments, and hospital equipment).

United Kingdom (MHRA): Transition and IMDRF Alignment

Following Brexit, Great Britain established the UKCA marking system under the UK Medical Devices Regulations 2002. Currently, the UK classification system mirrors the old EU Medical Devices Directive (MDD 93/42/EEC) framework.

However, the UK is undergoing regulatory reform:

CE Recognition Transition: Under the 2023 amendment, Great Britain accepts CE-marked devices on the market until June 30, 2028 (for devices CE-marked under the old MDD/AIMDD) or June 30, 2030 (for devices CE-marked under the current EU MDR/IVDR).
Future Regime and IMDRF Alignment: The MHRA’s future core regulations, expected to take effect gradually, will update the classification rules. The MHRA has committed to aligning its future core regime closely with the IMDRF’s classification principles, particularly for Software as a Medical Device (SaMD), to reduce administrative barriers for international manufacturers.

IMDRF (GHTF): The Harmonized Global Model

The International Medical Device Regulators Forum (IMDRF) inherited the classification principles developed by its predecessor, the Global Harmonization Task Force (GHTF). The foundational document, GHTF SG1/N15:2006, establishes a four-tier classification system designated by letters:

Class A (Lowest Risk): E.g., surgical drapes, examination gloves.
Class B (Low-Moderate Risk): E.g., syringes, diagnostic ultrasound.
Class C (Moderate-High Risk): E.g., lung ventilators, infusion pumps.
Class D (Highest Risk): E.g., pacemakers, implantable defibrillators.

The IMDRF model utilizes a rules-based framework similar to the EU MDR. The four-class principle — and its A–D lettering — forms the global harmonization baseline, though national regulators express it differently: Canada (Health Canada) and Brazil (ANVISA) use four numeric classes (I–IV); Singapore (HSA) and other ASEAN markets use A–D under the ASEAN Medical Device Directive; and Australia (TGA) applies EU MDR-style I/IIa/IIb/III classes built on the same GHTF risk principles.

2. The China NMPA Framework: A 3-Class Rules-Based Hybrid

When comparing global frameworks, it is important to include China’s National Medical Products Administration (NMPA). China’s system is a hybrid that combines the rules-based approach of the IMDRF with a highly structured classification catalog.

NMPA divides medical devices into three risk classes:

Class I (Low Risk): Regulated through local filing (备案). No clinical trial or Notified Body equivalent is needed.
Class II (Moderate Risk): Subject to provincial-level registration. Requires local testing in an NMPA-accredited laboratory and detailed technical file reviews.
Class III (High Risk): Managed at the national level by the Center for Medical Device Evaluation (CMDE) in Beijing. Max regulatory scrutiny, often requiring domestic clinical trials or comprehensive clinical evaluation reports (CERs) utilizing predicate data.

To determine a device's class in China, manufacturers must reference the NMPA Medical Device Classification Catalog (updated continuously, containing over 22 primary sub-catalogs). If a device is novel and not described in the catalog, the sponsor must submit a classification definition petition to the NMPA, similar to the US FDA De Novo or Q-Sub process.

3. Comparison Matrix: Side-by-Side System Mapping

The table below provides a comprehensive side-by-side comparison of the classification structures, determination methods, typical submission requirements, and regulatory support systems across the four jurisdictions:

Table 1: Medical Device Classification Comparison Matrix

Parameter	United States (FDA)	European Union (EU MDR)	United Kingdom (MHRA)	IMDRF Framework
Risk Classes	Three: Class I, II, III	Four: Class I, IIa, IIb, III	Four: Class I, IIa, IIb, III (Transitioning)	Four: Class A, B, C, D
Primary Method	Procodes & 21 CFR database lookup	Annex VIII (22 rules) assessment	UK MDR 2002 rules (moving to IMDRF rules)	GHTF SG1/N15 rules-based system
Subclass Division	None	Class I: Is (sterile), Im (measuring), Ir (reusable)	Class I: Sterile, Measuring, Reusable	None (Subclasses managed via national rules)
Premarket Reviewer	FDA (CDRH) staff	Private Notified Bodies (NBs)	Approved Bodies (ABs) or NBs	National Regulatory Authority
Lowest Class Path	General Controls (Self-registration)	Self-declaration of Conformity	Self-declaration (UKCA registration)	Self-declaration (Class A)
Moderate Class Path	510(k) premarket notification	Notified Body QMS & Tech File audit	Approved Body QMS & Tech File audit	Technical File review (Class B/C)
Highest Class Path	Premarket Approval (PMA)	NB Design Examination & QMS audit	AB Design Examination & QMS audit	Full premarket review (Class D)
Small Business Help	SBD program (Up to 75% fee discount)	None (Fees set by private NBs)	Limited (Varies by Approved Body)	Varies by national regulator
Submission Format	eSTAR (Mandatory for 510(k)/De Novo)	Technical Documentation (MDR Annex II/III)	Technical File (UK MDR 2002 format)	Table of Contents (ToC) or CSDT

Data source: FDA 21 CFR, EU MDR 2017/745, GOV.UK MHRA guidance, IMDRF GHTF SG1/N15; analysis by MedDeviceGuide.

4. Worked Examples of Classification Divergence

To illustrate how these differences function in practice, we examine three specific device types that land in different classes across the systems:

Example 1: Reusable Scalpel Handle

A stainless-steel scalpel handle designed to be sterilized and reused in surgical procedures.

US FDA: Class I. Product Code: GEA (Manual surgical instrument for general use, 21 CFR 878.4800). It is exempt from 510(k) and exempt from most GMP/QMSR requirements (except 820.180 and 820.198), representing the lowest regulatory tier.
EU MDR: Class Ir (Reusable surgical instrument). Under Annex VIII Rule 6 (transient use surgical invasive devices), it is Class I. However, because it is reusable, it falls under the Class Ir subclass. This requires a Notified Body to audit the reprocessing validation (cleaning and sterilization instructions) before the manufacturer can CE mark the device.
UK MHRA: Class I (Reusable). Currently matches the EU MDR approach, requiring an Approved Body audit of the sterilization/cleaning documentation.
IMDRF: Class A. Under GHTF SG1/N15 Rule 5, transient surgical invasive devices are Class A. Reprocessing controls are managed via general postmarket controls rather than a separate subclass premarket audit.

Example 2: Continuous Glucose Monitor (CGM)

A wearable sensor that monitors glucose levels in interstitial fluid and transmits data to a smartphone app.

US FDA: Class II. Product Code: QBJ (Integrated Continuous Glucose Monitoring System, iCGM). Requires a 510(k) or De Novo submission, aligning with the FDA's moderate-risk premarket clearance pathway.
EU MDR: Class IIb (Class III where it drives automated insulin dosing, or for implantable variants). Most CGMs are classified under Rule 11 (software informing therapy decisions) together with the active-device monitoring rules: a transcutaneous CGM that can guide insulin dosing lands in Class IIb, while implantable sensors or closed-loop control of an insulin pump rise to Class III.
UK MHRA: Class IIb / Class III. Transitioning to align with the EU MDR classification.
IMDRF: Class C / Class D. Under GHTF SG1/N15 Rule 10, active devices intended to monitor vital physiological parameters, where the nature of variations is such that it could result in immediate danger to the patient, are Class C. If the sensor is implantable, it rises to Class D.

Example 3: ECG Analysis Software (SaMD)

A standalone software application that analyzes ECG waveforms from a smart watch to detect atrial fibrillation.

US FDA: Class II. Product Code: QDA (Electrocardiograph software for over-the-counter use). Requires a 510(k) clearance, validating the algorithm's performance against reference databases.
EU MDR: Class III. Under Annex VIII Rule 11, software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes is Class IIa, except if such decisions have an impact that may cause death or irreversible deterioration of health, in which case it is Class III. Because misdiagnosing atrial fibrillation can lead to stroke or death, these algorithms are classified as Class III.
UK MHRA: Class IIb / Class III. The MHRA’s future regime intends to adopt a risk-classification model that aligns with the IMDRF SaMD framework, but current transitional rules classify it as Class IIa or IIb.
IMDRF: Class III (SaMD Category III). Under the IMDRF SaMD Risk Categorization framework, software that informs clinical management for a critical disease state is categorized as Category III (equivalent to Class C or D depending on the specific clinical scenario).

5. Software as a Medical Device (SaMD) Classification Rules

The rapid growth of digital health has forced regulators to update their software classification rules. Software cannot be classified using traditional criteria designed for physical hardware (such as "degree of invasiveness" or "duration of contact with the body").

The EU MDR: Rule 11

Under the old EU directive, most medical software was classified as Class I (low risk), allowing manufacturers to self-certify. The EU MDR resolved this by introducing Rule 11, which reads:

"Software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes shall be classified as Class IIa, except if such decisions have an impact that may cause:

death or irreversible deterioration of a person's state of health, in which case it is in Class III;

a serious deterioration of a person's state of health or a surgical intervention, in which case it is classified as Class IIb.

Software intended to monitor physiological processes shall be classified as Class IIa, except if it is intended for monitoring of vital physiological parameters, where the nature of variations of those parameters is such that it could result in immediate danger to the patient, in which case it is classified as Class IIb.

All other software is classified as Class I."

Rule 11 has effectively eliminated Class I software in Europe. Almost any clinical software provides information used for diagnostic or therapeutic decisions, placing it in Class IIa, IIb, or III. This requires Notified Body audits, QMS certification, and clinical evaluation reports for software products.

The FDA: Software Function Policies

The FDA’s approach is defined by the 21st Century Cures Act, which amended Section 520(o) of the FD&C Act to exclude certain software functions from the definition of a medical device (such as administrative software, lifestyle tracking, and certain clinical decision support software that allows the clinician to independently review the basis of the recommendation).

For software that remains a medical device, the FDA classifies it based on its specific function and clinical specialty (e.g., radiology diagnostics, cardiology analysis, psychiatric therapy) using product codes. The FDA evaluates the software's intended use and whether it functions autonomously or as a secondary decision-support tool.

The IMDRF SaMD Framework

The IMDRF developed a specialized risk categorization framework for SaMD based on two factors:

The State of the Healthcare Situation: Is it Critical, Serious, or Non-serious?
The Significance of the Information Provided by the SaMD: Does it Treat or Diagnose, Drive Clinical Management, or Inform Clinical Management?

This matrix yields four categories (I, II, III, IV), where Category IV represents the highest risk (e.g., software used to diagnose a critical condition like a stroke in an emergency setting). The MHRA is adopting this framework to govern UKCA software clearances.

6. Financial and Operational Timelines by Risk Class

Understanding the risk class is only the first step; manufacturers must prepare for the downstream financial and operational consequences. The table below provides benchmark costs and timelines associated with each risk class under the EU MDR and US FDA frameworks in 2026:

Table 2: Benchmark Registration Costs and Timelines by Risk Class

Risk Class	Framework	Typical Notified Body / FDA Review Fee	Median Audit & Review Timeline	Clinical Study Required?
Class I / A	FDA	$0 (Exempt)	Immediate (Electronic listing)	No
	EU MDR	€3,000–€5,000 (Internal costs)	1–2 months (Self-declaration)	No
Class IIa / B	FDA (510k)	$24,335 (Standard) / $6,084 (Small Business)	5–9 months (Calendar time)	Rarely (<10% of codes)
	EU MDR (IIa)	€15,000–€25,000 (Notified Body audit)	12–18 months	Sometimes (Clinical literature)
Class IIb / C	FDA (510k)	$24,335 (Standard) / $6,084 (Small Business)	6–10 months	Frequently (20–30% of codes)
	EU MDR (IIb)	€25,000–€45,000 (Notified Body audit)	14–20 months	Yes (Equivalence or clinical trial)
Class III / D	FDA (PMA)	$540,783 (Standard) / $135,196 (Small Business)	8–12 months	Yes (Pivotal clinical study)
	EU MDR (III)	€50,000–€90,000+ (Notified Body audit)	18–24+ months	Yes (Pivotal clinical study)

Data source: FDA MDUFA V fee schedules, representative EU Notified Body tariff sheets, and industry survey data collected by MedDeviceGuide.

These timelines show why a minor classification difference (e.g., landing in Class IIb instead of Class IIa under the EU MDR) can delay a launch by half a year and cost tens of thousands of Euros in additional audit fees.

7. Strategic Guidance for Multi-Market Compliance

If you are launching the same device in the US, EU, UK, and IMDRF-aligned markets, follow these strategic steps:

1. Identify the Highest Class First

Because the EU MDR and FDA use different methodologies, map your classifications early. If your device is Class IIa in the EU but Class I in the US, your premarket submission effort will be focused on Europe. If the device is Class III in the EU (due to Rule 11 or Rule 22) but Class II in the US, your US regulatory path (510(k)) will be significantly faster and cheaper than your European Notified Body review.

2. Do Not Assume "General Controls" are Equal

An FDA Class I device is often exempt from QMS/GMP design controls. However, the equivalent EU MDR Class I device (such as a Class Ir reusable instrument) requires a Notified Body audit of the reprocessing validation. Never assume that a low-risk classification in the US eliminates your quality system work in Europe.

3. Maintain a Single Technical File with Regional Modules

To minimize documentation duplication, structure your technical file according to the IMDRF Table of Contents (ToC) format. This format organizes clinical, preclinical, and manufacturing data into a core structure, allowing you to attach regional modules (such as the FDA eSTAR or the EU MDR GSPR checklist) as appendices.

Medical Device Classification FAQ

Is EU MDR Class I the same as FDA Class I?

No. While both represent the lowest risk category in their respective systems, their regulatory paths differ. An FDA Class I device is usually exempt from premarket notification and is often exempt from QMS design controls. An EU MDR Class I device is self-certified, but if it is sterile (Is), measuring (Im), or reusable (Ir), it requires a Notified Body audit of those specific features.

Does software (SaMD) classify the same under FDA, EU MDR, and IMDRF?

No. Software classification diverges significantly. Under EU MDR Rule 11, almost all software is Class IIa or higher, requiring Notified Body involvement. Under the FDA, some software functions are exempt from regulation entirely, while regulated software is classified as Class I, II, or III based on product codes. The IMDRF uses a unique four-tier SaMD risk matrix.

When multiple EU MDR classification rules apply, which one wins?

Under Annex VIII of the EU MDR, if a device has features that map to multiple classification rules, the rule that results in the highest risk classification governs.

Do I always need a Notified Body for EU MDR Class I devices?

No. Standard Class I devices (non-sterile, non-measuring, non-reusable) do not require a Notified Body. The manufacturer can self-declare conformity, register the device, and apply the CE mark. However, if the Class I device is sterile (Is), has a measuring function (Im), or is a reusable surgical instrument (Ir), a Notified Body must audit those specific features.

How does UK classification differ from EU MDR after Brexit?

Currently, Great Britain accepts CE-marked devices under transition timelines, and its domestic UKCA rules match the old EU MDD rules. However, the MHRA’s future core regulations will introduce updated rules, including aligning SaMD classification with the IMDRF four-tier risk framework, creating differences in software classification compared to the EU MDR.

Data sources: FDA product-code classification (7,075 product codes; class distribution computed by MedDeviceGuide); EU MDR Annex VIII and MDCG 2021-24 classification guidance; GOV.UK / MHRA UKCA and CE-recognition guidance; and IMDRF GHTF SG1/N15:2006. Product-code examples (GEA, QBJ, QDA) are drawn from the FDA product classification database. This article is educational and is not regulatory advice for a specific product or company.